 | ||||||||||
 |
 |
 |
|
 |
|
 |
|
 |
|
 |
|
|
|
| ||
Completed:
Planned: Viral Genetics is now completing studies related to its recent licensing of technology from the University of Colorado. The technology may explain the mechanism of action of TNP as well as identify its active components. The Company is now performing studies to confirm this as it would likely allow further optimization of the Company’s VGV-1 investigational drug prior to the next clinical trial(s). |
|
|
|
Home | About Us | Our Team | Advisory Board | Discovery Our Vision | Immune-Based Therapies | TNP | Development | VGV-1 History | Product Timeline | Clinical Trials Press Releases | Media Kits | Media Inquiries | News Subscription Service Investor Contacts | Email Alerts | Contact Us | SEC Filings Glossary | Stock Information | Corporate Governance & Board of Directors University of Colorado License | Careers |
|
|
 |
|
|
